Vertex licenses its first drug from CRISPR collaboration – BioPharma Dive
Labiotech.eu |
Vertex licenses its first drug from CRISPR collaboration
BioPharma Dive Vertex Pharmaceuticals Inc. has selected CTX001 as the first drug it will co-develop and commercialize with CRISPR Therapeutics AG per the companies' ongoing collaboration. Executives have already requested from regulators to conduct a Phase 1/2 trial … Vertex and CRISPR Therapeutics Partner on Gene Therapy for Blood Disorders Global CRISPR/Cas9 Tools Market Opportunity & Insights Report 2017 Crispr Therapeutics (CRSP) vs. Immunomedics (IMMU) Critical Analysis |
